Navigation Links
AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
Date:6/21/2013

REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June 27, 2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21 Club, 21 West 53rd Street, New York, NY.

Members of the AcelRx management team will present insights on the Company's Sufentanil NanoTab PCA System Phase 3 clinical trial results and discuss plans related to hospital formulary adoption and commercialization. In addition, thought leaders who treat post-operative pain in the hospital setting will discuss their experience with and perspectives on the Sufentanil NanoTab PCA System. Breakfast will be served for meeting attendees from 8:00 a.m. to 9:00 a.m. and a link to the live webcast will be available on the Investors page of the Company's website at www.acelrx.com beginning at 9:00 a.m. EDT. An archive of the webcast will be available shortly after the event through the Investors page at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. The NanoTab System has successfully completed all three of its planned Phase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013.  AcelRx has announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's Sufentanil NanoTab PCA System Phase 3 clinical trial results, planned New Drug Application submission, the Company's plans related to hospital formulary adoption and commercialization as well as planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission filings, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2013.  AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
2. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
3. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
4. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
5. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
7. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
8. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
9. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Provides Clinical Trial Updates
11. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
(Date:2/17/2017)... 17, 2017   Risperdal lawsuits involving gynecomastia (male ... with use of the atypical antipsychotic medication continue to ... Court of Common Pleas, where the state,s Risperdal docket ... to a notice posted on the Court,s website ... on March 9, 2017 at 11:00 a.m. (In Re: ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  BioDigital, ... today the partnership of their 3D body mapping ... healthcare IT.  The new integration will be used ... an interactive model of the human body. BioDigital ... saves clinicians time, while also increasing the precision ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the ... a visit this week at HIMSS 2017 Conference & Exhibition. The event brings ... Sensogram will be featured in the conference’s Connected Health Experience section, an area ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care ... partners, announced during the 2017 Annual HIMSS Conference & Exhibition in ... diabetic patients and integrating eye care into mainstream healthcare delivery is powered by ...
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
Breaking Medicine News(10 mins):